MMP2

matrix metallopeptidase 2, the group of M10 matrix metallopeptidases

Basic information

Region (hg38): 16:55389700-55506691

Previous symbols: [ "CLG4", "CLG4A" ]

Links

ENSG00000087245NCBI:4313OMIM:120360HGNC:7166Uniprot:P08253AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • multicentric osteolysis, nodulosis, and arthropathy (Strong), mode of inheritance: AR
  • multicentric osteolysis, nodulosis, and arthropathy (Strong), mode of inheritance: AR
  • multicentric osteolysis-nodulosis-arthropathy spectrum (Supportive), mode of inheritance: AR
  • Winchester syndrome (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Multicentric osteolysis, nodulosis, and arthropathy (Torg-Winchester syndrome)ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingDermatologic; Musculoskeletal5795345; 2625626; 9843039; 10861676; 10861675; 11431697; 15691365; 16542393; 17059372; 20720557; 20865259; 22876575

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the MMP2 gene.

  • Multicentric osteolysis nodulosis arthropathy spectrum (6 variants)
  • not provided (6 variants)
  • Multicentric osteolysis, nodulosis, and arthropathy (3 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the MMP2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
60
clinvar
10
clinvar
73
missense
1
clinvar
102
clinvar
2
clinvar
4
clinvar
109
nonsense
6
clinvar
1
clinvar
1
clinvar
8
start loss
1
clinvar
1
frameshift
5
clinvar
5
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
2
clinvar
1
clinvar
3
splice region
2
5
1
8
non coding
29
clinvar
29
clinvar
49
clinvar
107
Total 11 5 137 91 63

Highest pathogenic variant AF is 0.00000657

Variants in MMP2

This is a list of pathogenic ClinVar variants found in the MMP2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-55459530-GAGCCGAGATTACACCACTGCACTCCAGCCTGGCAATACAGCGAGACTCAGTCTCAAAAAAAAAAAAAAAAAAAAAAAGCAGCTCTATGTGACTCCCTCCCTCCCCCTACAAAAAAATAGAGGGTTCAGAGACTCAGTCAACAGCATTTCTGGTTCAACAAGCATCAAAACTAGCTGAGTTCTAGGTCACTGGGGTGGGGCAGAGGAGAGGTCTAAGGACATTTCACACCCTGACACCAGTCTGTCCTTTTCTTGGGGGTTATTTCCAACCACAGACTCCTTTGCAGCCTCAGAATCCCCGAAAGCAGCTCTCCCAGGCCCCACCCAGCTTCCCTCCTGCAGTGCTTATGCCCAGTTCATGCACCAGTCTCCAATCCAGCCATCTCCTCTCACCCCTGGCCCTCAGCTTCATTTGCCTGGGCCTGTGACACCCAAGGTCTTGGAACCCTATTAGGTTGGTGCAAAGGTAATTGTGGTTTTACCATTGAGTAAAACCACATTTACTTTTGCACCAATGTAATAGATGCTGAAAAAACGGCCTTGTTTGGGAGCTCAGGAAAGCAGCTGGCTGAATTCAGAGAGACAGGACTGACTGGGATCCCCACAATCCTCACTCTCCTGGGGAATGGCCCCTCCGAAAAGCACCCTGCAGCCCCCGGGCTGATTTCATTGGGATATGCAGGAAGCCAACCGCTCCTGCTCACAACAACTACTCAGCACTGACTGTGTTTCAGACACCATCCTCAGCATCAGATGAGCAAAATCTAACACTCTCAGATGCCATCTGAGGTGGGCTTACTGAATATCACCCTTGGAAAGATGTGGAATTGTAAAAGAAGAAAAAAGGACCTCCCTTTGCTAGAGTGGGATCTTATTTCCGGCAGCCAAAGAGGCCAGGGCTGAAAAACGCCCAAATGGCCTCTGAAGCAAAATCTCACGATGAAACAAGCCTCAAAAAGCATTTACTAGCATTTCTGGTCATGGCTGTTACGGATGAAATGGTGCCTCACCTTCTGCACCCCCTCTGGCCCCCACACCTTCTATGTTCCTATCTCAGGGATTCTCCACAGGGACCTGGAAGGACAGCTGAGTGGACCGAGAGATCACACGGAGCCACTGTGAGGGGTCAGGGGATAGGGAGAGTGAGCTGCCCAGGGTGGCTGCAGAGAGGGGAGCTTGGGGAACAGAGACCGCAGGGAGAAAGAGCTGAGTGCAGCCTGAGCCCGTGATTTTCAAGCCCCGCCGCTGGCCTCCTAGGGTTCTTGTAATCATACTCCGACTCCCTTCTCCTTAGTTAGTCTAAGGGGGCTTCTGTTTCTTGCTCCCAACTGCTGCCTCACTAAGATAGACTCATTTTCAGATCTCTCTACGGATTGTAGCCTTTCCTGCAATTCCTGCCTGGATGGCTGCTCCTCCAGGCCTGGACTGGATGGAAGGTTCCAAGCGAGAACCTGCAGCATTTCTGCTTCTGCGGCATCATCCACCTCTGAGAACCACTCCAGAGGACAAGCTGAGGAGCCTTCCAAGAGCTCCATGTGTCTGTAAATGCCTTCAAAACCTGGTCTCAGTGCATCCTTTTTGCACCCACAGCCAGATAGCTGACCACACAACATCAGGATAGAGTGGTCACCACCCATTTTCTGTCATGGGAAAGGAAATTGCCCGGGAAAGGCCTTGCCCAGTGCAGACATGGCAGGCAATGCTGAGAGCTACAAAATCCTTCTAGAAGCTGTTGTCTTTCAGTTATTAAGACTATAAGGGCTGGGCATGGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGTGGATCACAAGGTCAGGAGTTTGAGACCAGCCTGGCCAACATGGCAAAACCCTGTCTCTGCTAAAAATACAAAAAAAAAAAAAATGCGCATGCCTGTAATCCCAGTTACTTGGGAGACTGAGGCAGGAGAATCGCTTGAACCTGGGAGGTGGAGGTTGCAGTGAGCCGAGATCACGCCACTGCACTCCAGACTGGATGACAAAGCAAGACTCCATCACGGAAAAAAAAAAAAAAAAAAAGAAGGCAGGCTGCCTAGCTTAGCTTTGCCATGACTAATCTACTTACCAGCTAAGCAACATTTGTGCAAGCTATTTCACCTCTGTGTGCCTCAGTTTCTTCATCTATAAAATAGAGATAATCATTTTACACCCCTCAATAAATGTCTTTTGAATCAATTAATGAATACTTGTAAAACACCTGGCATATTGTAAGCCCTTGTTAAATGTAAACTTTAAATGTTAAATGGTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTTCCTGTTTCTGTTCTCTCTCTCTCTCTTTCCCTCTTTCTCTCTTTCTCTCTTGGAAGGTCTCACTCTGTTGCCCAGGCTGGAGAGCAGTAGTGCAATCATGGCTCACTGCCTACAACCCCACCGTAAGTCCCTCTGGGATTCCATGATAGAGGTACTTATTCCAATTAGGGTCAAGCTGGAGGAAGAGGCGGCTGTGGCCTAGCTGTCAATTCCTCAGGGCTGGTCATTGGGGAGGAAGGGCAGGAACCAGCTGAGTTCACTGAGAGTTGGAACAGGAGACGCAGAAAGGTACAGATTTGGAAACTGACCTGGGTATCACAGTTAGGGCTCCAGGGCACTCCAGCCTGCGGTGGGAGTTTGTAGGTGTCTAAGCTGTGGCTGGGAGGGCAGTGGAAGAAAGTCAAGCTGTGCCAATTTTCCTATTTGAAGAGAAAGGGAGCAGGGGAACCAGAGTTCTAGGTGACACCATCGGGAAGACAAGCTGTGTCCTCAGCCCGGCCTGGGGGGAGGACTGGGTTGCAACTTACAGGAAAGAGGATTGACTGGATTCTTAGAAAAACAAGAGCCAAGGCTTGTTGCTGTGCAGAGGGATTGGGGTCACCAGCTGGCTGTTGTTACCGTGACTGATTCCTGATGCTTCGGAATTCAAGGGCAGGAGGCACTTGGGGCACTGGCTGAACCTTGGCTCCCTGACCCCTCCTCAGTCCCCTTCCTGGGCTCCACAACATATAAGATGAACGTTCTGATTGTCTATTTCTCCTCCCTTCTCGTTTTACTCTTCATTTGGTGGAGTGTAT-G Familial hypokalemia-hypomagnesemia Likely pathogenic (Dec 18, 2018)617534
16-55477894-C-T Lip and oral cavity carcinoma association (Jan 01, 2016)429032
16-55479032-G-T Benign (Jun 19, 2021)1280738
16-55479277-T-TGCG Multicentric Osteolysis-Nodulosis-Arthropathy (MONA) Spectrum Disorders Uncertain significance (Jun 14, 2016)319740
16-55479279-C-G Multicentric osteolysis nodulosis arthropathy spectrum Uncertain significance (Jan 13, 2018)319741
16-55479333-T-A Multicentric osteolysis nodulosis arthropathy spectrum Uncertain significance (Jan 12, 2018)886975
16-55479366-G-A Multicentric osteolysis nodulosis arthropathy spectrum Uncertain significance (Jan 13, 2018)319742
16-55479419-G-C Multicentric osteolysis nodulosis arthropathy spectrum Benign (Jun 19, 2021)319743
16-55479473-C-A Multicentric osteolysis nodulosis arthropathy spectrum Uncertain significance (Jan 13, 2018)319744
16-55479478-C-A Multicentric osteolysis nodulosis arthropathy spectrum Uncertain significance (Jan 13, 2018)319745
16-55479479-GAT-G Uncertain significance (Jun 15, 2022)1967032
16-55479495-G-A Uncertain significance (Mar 27, 2022)1952742
16-55479499-G-A Uncertain significance (Oct 03, 2023)1411122
16-55479502-G-A Inborn genetic diseases Uncertain significance (Aug 24, 2023)2168908
16-55479509-C-T Likely benign (Aug 30, 2023)746207
16-55479511-C-T Uncertain significance (Dec 22, 2021)1966055
16-55479516-C-T Uncertain significance (Jul 06, 2022)1348855
16-55479517-C-G Multicentric osteolysis nodulosis arthropathy spectrum Uncertain significance (Jul 28, 2023)888242
16-55479522-A-C Likely benign (Jun 04, 2023)2972770
16-55479530-C-T Multicentric osteolysis nodulosis arthropathy spectrum • MMP2-related disorder Benign/Likely benign (Mar 01, 2024)319746
16-55479545-C-T Likely benign (Jul 06, 2022)1962045
16-55479572-G-A Likely benign (Dec 11, 2023)1539395
16-55479575-G-T Multicentric osteolysis nodulosis arthropathy spectrum Conflicting classifications of pathogenicity (Nov 29, 2023)729361
16-55479584-C-T Conflicting classifications of pathogenicity (May 22, 2023)193285
16-55479592-C-T Uncertain significance (Nov 22, 2022)1910123

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
MMP2protein_codingprotein_codingENST00000219070 13116992
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.8390.1611257260221257480.0000875
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.7103513900.8990.00002464364
Missense in Polyphen146173.350.842231850
Synonymous-1.271781581.130.00001061242
Loss of Function4.30632.40.1850.00000168364

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00006150.0000615
Ashkenazi Jewish0.00009920.0000992
East Asian0.0001680.000163
Finnish0.0001850.000185
European (Non-Finnish)0.00005300.0000527
Middle Eastern0.0001680.000163
South Asian0.0002290.000229
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14.; FUNCTION: Isoform 2: Mediates the proteolysis of CHUK/IKKA and initiates a primary innate immune response by inducing mitochondrial-nuclear stress signaling with activation of the pro- inflammatory NF-kappaB, NFAT and IRF transcriptional pathways.;
Disease
DISEASE: Multicentric osteolysis, nodulosis, and arthropathy (MONA) [MIM:259600]: An autosomal recessive syndrome characterized by severe multicentric osteolysis with predominant involvement of the hands and feet. Additional features include coarse face, corneal opacities, patches of thickened, hyperpigmented skin, hypertrichosis and gum hypertrophy. {ECO:0000269|PubMed:11431697, ECO:0000269|PubMed:15691365, ECO:0000269|PubMed:16542393}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Relaxin signaling pathway - Homo sapiens (human);AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human);Bladder cancer - Homo sapiens (human);GnRH signaling pathway - Homo sapiens (human);Estrogen signaling pathway - Homo sapiens (human);Fluid shear stress and atherosclerosis - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Leukocyte transendothelial migration - Homo sapiens (human);Matrix Metalloproteinases;Angiogenesis overview;AGE-RAGE pathway;MAPK6-MAPK4 signaling;Photodynamic therapy-induced AP-1 survival signaling.;Photodynamic therapy-induced NF-kB survival signaling;Lung fibrosis;VEGFA-VEGFR2 Signaling Pathway;Protein alkylation leading to liver fibrosis;Interleukin-4 and 13 signaling;EMT transition in Colorectal Cancer;Signal Transduction;inhibition of matrix metalloproteinases;MAPK6/MAPK4 signaling;Collagen degradation;Metabolism of proteins;Extracellular matrix organization;ATF-2 transcription factor network;Activation of Matrix Metalloproteinases;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);MAPK family signaling cascades;Degradation of the extracellular matrix;Angiopoietin receptor Tie2-mediated signaling;Direct p53 effectors;Osteopontin-mediated events;Regulation of nuclear beta catenin signaling and target gene transcription;LPA receptor mediated events;amb2 Integrin signaling;Plasma membrane estrogen receptor signaling;FOXM1 transcription factor network;Validated transcriptional targets of AP1 family members Fra1 and Fra2;Syndecan-2-mediated signaling events (Consensus)

Recessive Scores

pRec
0.962

Intolerance Scores

loftool
0.202
rvis_EVS
-0.06
rvis_percentile_EVS
48.84

Haploinsufficiency Scores

pHI
0.878
hipred
Y
hipred_score
0.749
ghis
0.562

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.725

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Mmp2
Phenotype
growth/size/body region phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); muscle phenotype; neoplasm; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; respiratory system phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype;

Zebrafish Information Network

Gene name
mmp2
Affected structure
interrenal angiogenic sprout
Phenotype tag
abnormal
Phenotype quality
decreased length

Gene ontology

Biological process
angiogenesis;response to hypoxia;blood vessel maturation;intramembranous ossification;proteolysis;embryo implantation;cytokine-mediated signaling pathway;extracellular matrix disassembly;extracellular matrix organization;collagen catabolic process;endodermal cell differentiation;cellular protein metabolic process;ephrin receptor signaling pathway;tissue remodeling;face morphogenesis;bone trabecula formation;cellular response to amino acid stimulus;positive regulation of vascular smooth muscle cell proliferation
Cellular component
extracellular region;extracellular space;nucleus;mitochondrion;plasma membrane;sarcomere;collagen-containing extracellular matrix
Molecular function
metalloendopeptidase activity;serine-type endopeptidase activity;protein binding;metallopeptidase activity;zinc ion binding